These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25503514)

  • 1. A decade of innovation in pharmaceutical R&D: the Chorus model.
    Owens PK; Raddad E; Miller JW; Stille JR; Olovich KG; Smith NV; Jones RS; Scherer JC
    Nat Rev Drug Discov; 2015 Jan; 14(1):17-28. PubMed ID: 25503514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
    Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in processes and priorities needed for new drug development.
    Wilson JF
    Ann Intern Med; 2006 Nov; 145(10):793-6. PubMed ID: 17116936
    [No Abstract]   [Full Text] [Related]  

  • 7. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
    J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rebuilding the R&D engine in big pharma.
    Garnier JP
    Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Science, medicine and... the markets.
    Pawlotsky JM
    J Hepatol; 2006 Sep; 45(3):341-2. PubMed ID: 16854496
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical futures: made in China?
    Cyranoski D
    Nature; 2008 Oct; 455(7217):1168-70. PubMed ID: 18971994
    [No Abstract]   [Full Text] [Related]  

  • 11. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing structure of the pharmaceutical industry.
    Cockburn IM
    Health Aff (Millwood); 2004; 23(1):10-22. PubMed ID: 15002624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A more rational approach to new-product development.
    Bonabeau E; Bodick N; Armstrong RW
    Harv Bus Rev; 2008 Mar; 86(3):96-102, 134. PubMed ID: 18411967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Pharma merges, R&D is the dowry.
    Agnew B
    Science; 2000 Mar; 287(5460):1952-3. PubMed ID: 10755948
    [No Abstract]   [Full Text] [Related]  

  • 17. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can open-source R&D reinvigorate drug research?
    Munos B
    Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.